These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10389284)

  • 1. Relationship between hormone receptor concentration and tumor shrinkage in uterine myoma after treatment with a GnRHa.
    Wang PH; Lee WL; Chao HT; Shu LP; Kao HL; Wu CW; Yuan CC
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):294-9. PubMed ID: 10389284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uterine myoma after cessation of gonadotropin-releasing hormone agonist: ultrasound and histopathologic findings.
    Wang PH; Yang AH; Yuan CC; Lee WL; Chao HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Nov; 61(11):625-9. PubMed ID: 9872018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen and progesterone receptor content of enucleated uterine myomata after luteinizing hormone-releasing hormone. Analogue depot therapy.
    Cirkel U; Ochs H; Roehl A; Schneider HP
    Acta Obstet Gynecol Scand; 1994 Apr; 73(4):328-32. PubMed ID: 8160541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of estrogen and progesterone receptors in the myometrium and leiomyoma tissue after suppression of estrogens with gonadotropin releasing hormone analogs.
    van de Ven J; Sprong M; Donker GH; Thijssen JH; Mak-Kregar S; Blankenstein MA
    Gynecol Endocrinol; 2001 Dec; 15 Suppl 6():61-8. PubMed ID: 12227888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of goserelin (Zoladex) in the treatment of uterine myomas in infertile patients.
    Kopitović V; Bujas M; Fistes Topalski N; Pjević M; Ilić D; Kapamadzija A; Bujas I
    Med Pregl; 2001; 54(7-8):339-46. PubMed ID: 11905182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure.
    Bozzini N; Rodrigues CJ; Petti DA; Bevilacqua RG; Gonçalves SP; Pinotti JA
    Acta Obstet Gynecol Scand; 2003 Apr; 82(4):330-4. PubMed ID: 12716317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
    Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
    Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Usefulness of Doppler ultrasound in predicting the effect of gonadotropin-releasing hormone agonist (GnRHa) on myoma uteri].
    Yoshioka N
    Nihon Sanka Fujinka Gakkai Zasshi; 1995 Nov; 47(11):1255-60. PubMed ID: 8543851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
    Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
    Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphological changes in uterine leiomyomas treated by GnRH agonist goserelin.
    Crow J; Gardner RL; McSweeney G; Shaw RW
    Int J Gynecol Pathol; 1995 Jul; 14(3):235-42. PubMed ID: 8600075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between gonadotropin-releasing hormone agonist and myoma cellular activity: preliminary findings on positron emission tomography.
    Lee WL; Liu RS; Yuan CC; Chao HT; Wang PH
    Fertil Steril; 2001 Mar; 75(3):638-9. PubMed ID: 11239559
    [No Abstract]   [Full Text] [Related]  

  • 12. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
    Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
    Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
    Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
    J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different expression of estrogen receptors alpha and beta in human myometrium and leiomyoma during the proliferative phase of the menstrual cycle and after GnRHa treatment.
    Wang H; Wu X; Englund K; Masironi B; Eriksson H; Sahlin L
    Gynecol Endocrinol; 2001 Dec; 15(6):443-52. PubMed ID: 11826769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.
    Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM
    Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
    Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research on the relationship between estrogen receptor, progesterone receptor, cell proliferation associated antigen in uterine leiomyoma and nuclear body density of myoma, serum reproductive hormone concentrations].
    Wu J; Cheng Y
    Zhonghua Fu Chan Ke Za Zhi; 1995 Oct; 30(10):603-7. PubMed ID: 8745507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
    Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro.
    Chung YJ; Chae B; Kwak SH; Song JY; Lee AW; Jo HH; Lew YO; Kim JH; Kim MR
    Int J Med Sci; 2014; 11(3):276-81. PubMed ID: 24516352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A comparative efficacy study of the preoperative use of GnRH agonists in women with uterine fibromyomas].
    Nikolov A; Karag'ozov I
    Akush Ginekol (Sofiia); 1999; 38(4):38-42. PubMed ID: 10726353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.